Abstract:Abstract Abstract: TSH-secreting adenoma (TSHoma) occupies less than 1% of pituitary adenomas and coexisting TSHoma is the rarer type(1). Few reports are available on the characteristics of coexisting TSHomas. To summarize the clinical, histological features and therapeutic outcomes of coexisting TSHomas, we retrospectively analyzed 51 patients (16 and 35 cases of coexisting TSHomas and pure TSHomas) diagnosed from January 2012 to April 2018 in a single center. A rate of mixed GH (68.8%) , GH+PRL (18.7%) and PRL adenomas (12.5%) were involved in our coexisting TSHoma population. Coexisting TSHomas had significantly longer median disease duration (84.0 vs 24.0 months, P=0.023), a larger rate of male patients (75.0% vs 40.0%, P=0.020), thyroid volume (41.8±17.3 cm3 vs 19.6±8.4cm3, P=0.003), tumor maximum diameter (28.2± 14.7 mm vs 15.8±9.3 mm, P=0.009), tumor volume (6.9 cm3 vs 1.0 cm3, P=0.002) and a higher ratio of cavernous sinus invasion (defined as Knosp≥3, 56.3% vs 6.5%, P=0.001). The effects of preoperative medical and surgical treatment were assessed. In preoperative medical treatment, coexisting TSHomas patients achieved a similar ratio of thyroid function normalization and tumor shrinkage≥20% with a longer course of treatment with somatostatin analogs (4.8 times vs 3.0 times, P=0.006) when compared with pure TSHomas. Coexisting TSHomas patients yielded a lower percentage of euthyroid remission (50.0% vs 92.9%, P=0.039) and complete remission (12.5% vs 92.9%, P=0.000) than pure TSHomas on the first day after the operation and a lower complete remission rate within six postoperative months (0% vs 69.2% , P=0.011). The univariate analysis showed that higher TSH levels at diagnosis may be an unfavorable factor affecting tumor shrinkage, and coexisting tumors were significantly correlated with poor euthyroid and complete remission rates on the first day after surgery. We speculate that coexisting tumors may require a longer period of preoperative pharmacotherapy and attain a high recurrence rate in the short term. Reference: (1) Molitch et al., Jama, 2017Feb, 317(5):516-524. Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.

Clinical Features and Therapeutic Outcomes of GH/TSH Cosecreting Pituitary Adenomas: Experience of a Single Pituitary Center

Clinical Characteristics and Management of Cosecreting Thyroid Stimulating Hormone or Prolactin Pituitary Growth Hormone Adenomas: A Case-Control Study

Four patients with pituitary GH/PRL/TSH mixed adenoma: case studies and literature review

[Thyrotropin-secreting pituitary adenomas: clinical features and results of treatment in 45 patients]

MON-LB100 Worse Clinical Characteristics and More Unsatisfactory Therapeutic Outcomes in Coexisting Thyrotropin Pituitary Adenomas

Clinical Characteristics, Diagnosis, and Treatment of Thyroid Stimulating Hormone-Secreting Pituitary Neuroendocrine Tumor (TSH PitNET): A Single-Center Experience

Clinical characteristics and treatment of pituitary thyrotropin mixed secreting adenoma

Patients with true mixed growth hormone and prolactin-secreting pituitary adenoma: a case series of 12 patients

Pleiomorphism Plurihormonal Pit-1-positive Macroadenoma with Central Hyperthyroidism: a Rare Case Report and Literature Review

The Diagnosis and Treatment of Growth Hormone Secreting Pituitary Adenomas: Analysis of 95 Cases

[A Clinical Analysis of Thyrotropin-Secreting Pituitary Adenomas in 20 Patients].

[Clinical case of plurihormonal pituitary adenoma (STH/ACTH/TSH/FSH/LH-secreting), diagnostic pitfalls]

Epco-35. Genomic Characterization Of Growth Hormone Secreting Pituitary Adenomas

Mixed thyrotropin-secreting pituitary neuroendocrine tumor coexisting with Graves' disease: a case report

Pathogenesis, clinical features, and treatment of plurihormonal pituitary adenoma

[Thyroid-stimulating hormone pituitary adenomas: clinical characteristics, diagnosis and treatment]

Thyrotropin-secreting Pituitary Adenomas: Diagnosis and Management of Patients from One Chinese Center

Mixed Gangliocytoma-Pituitary Adenoma: A Systematic Review of Diagnostic Features, Clinical Management, and Surgical Outcomes

Mixed Gangliocytoma/pituitary Adenoma: a Clinicopathologic Study of Four Cases and Review of Literature

Diagnosis and Treatment of Pediatric and Adolescent Pituitary Adenomas:A Report of 42 Cases

Transsphenoidal Surgery of Giant Pituitary Adenoma: Results and Experience of 239 Cases in A Single Center